Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10283500 | 1.00 | PRKCA (0.42) | PRKCAMMP12KDM2BRAB9ASCN9A | |
| SCHEMBL12427983 | 0.92 | PRKCA (0.44) | PRKCAMMP12SCN9ANR1I2KCNH2 | |
| SCHEMBL10283257 | 0.91 | PRKCA (0.45) | PRKCAMMP12SCN9ANR1I2KCNH2 | |
| SCHEMBL12427975 | 0.91 | PRKCA (0.41) | PRKCAMMP12KDM2BRAB9ASCN9A | |
| SCHEMBL12428498 | 0.91 | PRKCA (0.41) | PRKCAMMP12KDM2BRAB9ASCN9A | |
| SCHEMBL12428522 | 0.91 | PRKCA (0.41) | PRKCAMMP12KDM2BRAB9ASCN9A | |
| SCHEMBL12428366 | 0.91 | PRKCA (0.41) | PRKCAMMP12KDM2BRAB9ASCN9A | |
| SCHEMBL10283575 | 0.90 | PRKCA (0.42) | PRKCAMMP12KDM2BSCN9ANR1I2 | |
| SCHEMBL12427984 | 0.90 | PRKCA (0.42) | PRKCAMMP12SCN9ANR1I2KCNH2 | |
| SCHEMBL12428525 | 0.89 | PRKCA (0.42) | PRKCAMMP12KDM2BSCN9ANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | PRKCA 2404/4885MMP12 1013/4885KDM2B 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.